SGLT2-Inhibition in Patients With Alport Syndrome

SGLT2-Inhibition in Patients With Alport Syndrome

Introduction: Large-scale trials showed positive outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD). Whether the use of SGLT2i is safe and effective in patients with the common hereditary CKD Alport syndrome (AS) has not yet been investigated s...

Full description

Saved in:
Bibliographic Details
Main Authors: Jan Boeckhaus, Daniel P. Gale, James Simon, Jie Ding, Yanqin Zhang, Carsten Bergmann, A. Neil Turner, Matthew Hall, John A. Sayer, Shalabh Srivastava, Hee Gyung Kang, Agne Cerkauskaite-Kerpauskiene, Valentine Gillion, Kathleen J. Claes, Bastian Krueger, Jonathan de Fallois, Ulrike Walden, Mira Choi, Markus Schueler, Roman-Ulrich Mueller, Polina Todorova, Bernd Hohenstein, Michael Zeisberg, Tim Friede, Bertrand Knebelmann, Jan Halbritter, Oliver Gross
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Kidney International Reports
Subjects:
albuminuria
Alport syndrome
COL4
dapagliflozin
empagliflozin
kidney failure
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924019429
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468024924019429

Similar Items